SG, W., SS, H., YL, T., & J, Z. (2026). Survival trends among patients with newly diagnosed stage IVB cervical cancer before and after the approval of bevacizumab and immunotherapy. European journal of obstetrics, gynecology, and reproductive biology, 321, 115045. https://doi.org/10.1016/j.ejogrb.2026.115045
Chicago Style (17th ed.) CitationSG, Wu, Hong SS, Tang YL, and Zhou J. "Survival Trends Among Patients with Newly Diagnosed Stage IVB Cervical Cancer Before and After the Approval of Bevacizumab and Immunotherapy." European Journal of Obstetrics, Gynecology, and Reproductive Biology 321 (2026): 115045. https://doi.org/10.1016/j.ejogrb.2026.115045.
MLA (9th ed.) CitationSG, Wu, et al. "Survival Trends Among Patients with Newly Diagnosed Stage IVB Cervical Cancer Before and After the Approval of Bevacizumab and Immunotherapy." European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 321, 2026, p. 115045, https://doi.org/10.1016/j.ejogrb.2026.115045.
